Effects of Cannabis (Tetrahydrocannabinol) on the Body
Cannabis has significant effects on the body including potential therapeutic benefits for chemotherapy-induced nausea and non-cancer pain, but also carries substantial risks including cognitive impairment, cardiovascular effects, respiratory issues, and psychiatric complications.
Pharmacology and Mechanism of Action
- Cannabis contains over 140 pharmacologically active cannabinoids, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most prominent 1
- THC produces effects through interaction with the endocannabinoid system via:
- CB1 receptors (present in cerebral cortex, hippocampus, basal ganglia, cerebellum, peripheral nervous system) - responsible for euphoric effects
- CB2 receptors (primarily on immune system cells) 1
- The pharmacokinetics vary by administration route:
- Inhaled cannabis: Effects begin within seconds to minutes, peak at 15-30 minutes, last 2-3 hours
- Oral cannabis: Effects begin after 30-90 minutes, peak at 2-3 hours, last 4-12 hours 1
- THC concentrations have increased dramatically in recent years, from 9% in 2008 to 17% in 2017, with concentrates reaching up to 70% THC 1, 2
Potential Therapeutic Benefits
- May improve chemotherapy-induced nausea and vomiting when standard antiemetics are inadequate
- May help with non-cancer pain
- No evidence supports using cannabis to treat cancer itself 1
- Other potential therapeutic applications under investigation include:
- Treatment for HIV/AIDS cachexia
- Multiple sclerosis spasticity
- Neuropathic pain 1
Adverse Effects
Acute Effects
Cognitive Effects:
Cardiovascular Effects:
Psychological Effects:
Other Acute Effects:
Chronic Effects
Neurological Effects:
Psychiatric Effects:
Respiratory Effects:
Cardiovascular Effects:
Special Considerations
Drug Interactions
- Cannabis inhibits cytochrome P450 enzymes (CYP3A4, UGT1A9, UGT2B7, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19)
- High-risk interactions with:
- Warfarin (very high risk)
- Buprenorphine and tacrolimus (high risk)
- May interact with chemotherapeutics, potentially affecting toxicity or efficacy 1
- Cannabis may reduce efficacy of immunotherapies 1
Vulnerable Populations
- Adolescents: Higher risk of negative impacts on brain development and cognitive function 1, 2
- Older adults: Increased risk of confusion and falls 1
- Individuals with history of psychosis: Higher risk of psychotic symptoms 1
- Patients on immunotherapy: May reduce treatment efficacy 1
Clinical Recommendations
For patients considering cannabis use:
- Start with the lowest possible dose and increase slowly
- Allow sufficient time between doses to gauge effects
- Be cautious with edibles as onset may be ≥1 hour after ingestion
- Avoid "stacking" doses to prevent adverse effects 1
For patients using cannabis:
For healthcare providers:
Common Pitfalls and Caveats
- Edible cannabis products have delayed onset (up to 2 hours), which can lead to overconsumption and more intense effects due to higher blood concentrations of 11-hydroxytetrahydrocannabinol 1
- Administration with high-fat meals significantly increases oral cannabinoid absorption and may exacerbate effects 1
- Cannabis is federally illegal in the United States despite state-level legalization in many areas 1
- Evidence on long-term effects remains limited due to research restrictions 1
- The perception of cannabis as a benign substance contradicts emerging evidence of significant adverse effects 5, 4